3 Ways Clinical Trial Diversity Can Put Sponsors On Top

By Carolyn Gretton, Content Writer, Citeline

In April 2022, the draft guidance document on diversity plans aimed at enhancing the participation of underrepresented racial and ethnic groups in clinical trials was released by the U.S. Food and Drug Administration (FDA). Subsequently, the industry has intensified its endeavors to ensure the integration of diversity at crucial junctures in the clinical trial process.

These efforts are crucial, given that, despite an escalating emphasis on diversity, the FDA observed that white patients comprised 69% to 77% of all clinical trial participants annually from 2017 to 2020. Moreover, the enrollment percentages of nonwhite patients in clinical trials exhibited minimal growth during that period.

Recognizing the significance of diverse clinical trials, the author has highlighted three pivotal reasons that stand out for companies aspiring to maintain a leading position in the life sciences industry.